Tyme Technologies Inc. (TYME)

[axelvento]

Conclusion ZERO DILUITION

The Eagle Pharmaceuticals partnership is a major event for Tyme, SM-88, and Tyme's shareholders. Now, the company has a reputable partner who appears to be motivated to grow the oncology arm of their business with SM-88. Together, Tyme and Eagle will work to get SM-88 on the market for pancreatic cancer and other SM-88 pipeline programs. Although I was hoping to see a big-name partner for SM-88, the details of the partnership are beneficial for Tyme, who will get a must-needed injection of cash and will have the option to reacquire the full-rights of SM-88 if they are interested. What is more, Tyme has dosed their first patient in their second SM-88-Panc study, with which the company is one step closer to potentially triggering another milestone payment from Eagle. As a result, Tyme could operate at their current OpEx over the next two years with minimal or no dilution. Admittedly, I don't know if the company will drastically ramp up cash burn with their SM-88 and TYME-18 R&D efforts, but I don't foresee the need for multiple offerings until the company is much closer to commercialization. At that point in time, I would expect the share price to be substantially higher than what it is currently trading at. Therefore, I am looking to add to my undersized TYME investment over the course of 2020 in anticipation of a monumental 2021.